VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Canary Medical, a medical data company focused on the development and commercialization of its patented implantable sensor technology and complementary data and analytics ecosystem, today announced the introduction of its first orthopedic analytic module, Canary Quantiles™ Recovery Curves. Recovery curves utilize movement data measured by Canary Medical’s proprietary implantable canturio™te tibial extension sensor technology integrated with Zimmer Biomet’s Persona IQ® - The Smart Knee®.

Read more from the original source:
Canary Medical Announces Introduction of Groundbreaking Orthopedic Analytic Platform

ATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced that it has agreed to an amendment to its existing loan and security agreement with its debt facility partner, SLR Investment Corp (“SLR”) to extend the interest-only period through March 31, 2023 with the possibility of extending to July 1, 2023.

More here:
Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement

MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the initiation of a clinical study evaluating the safety, tolerability profile, and intubation conditions of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

See the article here:
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery

Media Release

More:
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

Intranasal administration of Ampligen demonstrated to be well-tolerated

More:
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Company also announces that Julia Haller, MD, is stepping down from its Board of Directors Company also announces that Julia Haller, MD, is stepping down from its Board of Directors

More:
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President

The Company will Provide an Overview of its Immune Checkpoint Enhancer (ICE) Platform

View original post here:
AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases

Expands Commercialization Efforts in Areas with High Unmet Needs Expands Commercialization Efforts in Areas with High Unmet Needs

Here is the original post:
Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America.

Follow this link:
T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial...

VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical trial, for novel anti-aging compound TFC-1326, started on December 5th, 2022.

Read more here:
Sirona Biochem Announces Start of Clinical Trial for Anti-Aging Compound TFC-1326

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Committee (IDMC) for its Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia (AML) performed its initial prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. The charter for the IDMC provides for periodic reviews by the IDMC for safety, efficacy and futility in addition to the interim and final analyses.

Read more from the original source:
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the National Medical Products Administration (“NMPA”) in China has granted DANYELZA (naxitamab-gqgk) 40mg/10ml conditional approval. DANYELZA will be marketed in China by Y-mAbs’ partner SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”).

See original here:
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China

COPENHAGEN, Denmark, December 8, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to issue warrants to members of the Executive Management and selected employees in the Bavarian Nordic Group. As a new initiative, vesting of the warrants for members of the Executive Management will be based on successful achievement of relevant Key Performance Indicators (KPI's). The decision is made in accordance with the shareholder authorizations for the Board of Directors adopted as Articles 5b and 5c of the Articles of Association and the Remuneration Policy.

Read the original:
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

NEW YORK and MAINZ, GERMANY, DECEMBER 8, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. Children in this age group can receive a primary series consisting of two 3-µg doses of the original Pfizer-BioNTech COVID-19 Vaccine followed by a third 3-µg dose of the bivalent vaccine to complete the primary series. Vaccine doses can be delivered immediately upon receipt of a recommendation from the U.S. Centers for Disease Control and Prevention ("CDC").

The rest is here:
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

Continued here:
Voting Rights and Shares Capital of the Company

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced acceptance of two abstracts presenting patient data on its targeted therapeutics delivery system for presentation at the Crohn’s & Colitis Congress, which will take place January 19-21, 2023, in Denver, Colorado. This annual conference, a partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association, is focused on bringing together a multidisciplinary community of health care practitioners and researchers to transform inflammatory bowel disease care.

Here is the original post:
Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress

– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis –

View original post here:
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

Continued here:
Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022

MORRISTOWN, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, is pleased to share that The American Journal of Pathology has published results of a new study evaluating the link between cholestatic liver disease and cognitive impairment in mouse and human cell models. The study, which is the first to explore drug-based treatment response for cholestatic-related cognitive impairment, also evaluated the impact of anti-cholestatic therapies ursodeoxycholic acid (UDCA), obeticholic acid (OCA) and bezafibrate on their potential to reverse cognitive impairment and found that only OCA demonstrated potential efficacy.

Read more:
New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic...

Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries

The rest is here:
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model